Pfizer’s PDE4 inhibitor shows early efficacy in psoriasis, atopic dermatitis

Patients with atopic dermatitis and plaque psoriasis who were treated with a topical phosphodiesterase 4 inhibitor exhibited significant improvement, according to a study.
“Topical PF-07038124 is designed to be a potent, oxaborole-based [phosphodiesterase 4 (PDE4)] inhibitor with immunomodulatory activity in T-cell–based assays, contributing to inhibition of IL-4 and IL-13; thus, it could provide therapeutic benefit in the treatment of AD and plaque psoriasis, Lawrence F. Eichenfield, MD, of the department of dermatology at the University of California, San Diego School of

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart